[Effect of 99Tc-MDP on cytokine production by peripheral blood mononuclear cells of patients with rheumatoid arthritis].
OBJECTIVE
To study the immune mechanism of 99Tc-MDP in the treatment of patients with rheumatoid arthritis (RA).


METHODS
In vitro, 99Tc-MDP was added to the cultures of peripheral blood mononuclear cells (PBMC) derived from healthy subjects and RA patients. The levels of IL-1 and sIL-2R from PBMC affected by 99Tc-MDP were determined with enzyme linked immunosorbert assays (ELISA).


RESULTS
The IL-1 production by PBMC of RA, either in the medium alone (spontaneously) or in the presence of lipopolysacchride (LPS) stimulation, was suppressed by 99Tc-MDP; and the sIL-2R by PBMC of RA, either in the medium alone (spontaneously) or in the presence of phytohemagglutinin (PHA) induction, was inhibited by 99Tc-MDP.


CONCLUSIONS
99Tc-MDP acts on PBMC and a possible immune activity by 99Tc-MDP is related to the suppression of IL-1 and sIL-2R in RA patients.
Wu
Yong-gang
YG
Department of Nuclear Medicine, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Ma
Qi-lin
QL
Liu
Guo-feng
GF
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000328:Adult; D001172:Arthritis, Rheumatoid / Q000097:blood*; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000378:metabolism*; D008297:Male; D015375:Receptors, Interleukin-2 / Q000378:metabolism*; D013669:Technetium Tc 99m Medronate / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D007375:Interleukin-1; D015375:Receptors, Interleukin-2; D013669:Technetium Tc 99m Medronate